{"entity":{"id":"nct04570423","kind":"trial","name":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","aka":[],"tldr":"A phase 2 trial of Eflapegrastim in non-Hodgkin lymphoma, run by Spectrum Pharmaceuticals, Inc, now recruiting.","summary":"A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy is a phase 2 interventional study registered as NCT04570423 by Spectrum Pharmaceuticals, Inc, with 40 participants planned, started 2021-05-20 and due to reach its primary completion in 2027-10. Interventions recorded: Eflapegrastim and Chemotherapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04570423","url":"https://clinicaltrials.gov/study/NCT04570423"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":["cytokine-therapy"],"targets":[],"drugs":["eflapegrastim"],"companies":["spectrum-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04570423","phase":"2","setting":"A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Patients With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy","sponsor":"Spectrum Pharmaceuticals, Inc","participation":[{"nct":"NCT04570423","source":"https://clinicaltrials.gov/study/NCT04570423","fetchedAt":"2026-10-07T16:53:22.534Z","studySha256":"fd35979536f1294fa3c74769e6a4df65894b05a95ad7cf262672d1ea8c0a77ad","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-30","leadSponsor":"Spectrum Pharmaceuticals, Inc","collaboratorCount":0,"minimumAge":"1 Month","maximumAge":"17 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":40,"enrolmentType":"ESTIMATED","siteCount":5,"recruitingSiteCount":1,"countries":["United States"]}],"started":"2021-05-20","startedType":"actual","enrolled":40,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04570423/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"technology":[{"id":"cytokine-therapy","kind":"technology","name":"Cytokines & engineered cytokines","route":"/technologies/cytokine-therapy/"}],"drug":[{"id":"eflapegrastim","kind":"drug","name":"Eflapegrastim","route":"/drugs/eflapegrastim/"}],"company":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/"}]}}